Dr. Christopher J. Darus, MD
Gynecologic Oncology (Gynecologic Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Wright State University Boonshoft School of Medicine (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 35
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: Wright State University Boonshoft School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gynecologic Oncology Physician primary
OR license MD201361 · ME license MD17420 -
Obstetrics & Gynecology Physician
OR license MD201361 · VA license 0116016828
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Providence Portland Medical Center Portland, OR
- Providence Willamette Falls Medical Center Oregon City, OR
Medical groups
- Providence Health and Services Oregon (1,433 clinicians)
- Legacy Clinics LLC (713 clinicians)
- Salem Health (454 clinicians)
- Providence Health and Services - Oregon (191 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 35
- Services billed
- 236
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 45 | 15 |
| Established patient office or other outpatient visit, 40-54 minutes | 22 | 14 |
| New patient office or other outpatient visit, 60-74 minutes | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prochlorperazine Maleate Other prescribers in Portland, OR | 27 |
| Ondansetron Hcl Other prescribers in Portland, OR | 18 |
| Ondansetron Odt (ondansetron) Other prescribers in Portland, OR | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 23 payments worth $9,578 in total to this clinician.
| Corcept Therapeutics | $5,440 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $2,901 |
| Intuitive Surgical, Inc. | $747 |
| Conmed Corporation | $125 |
| AbbVie Inc. | $124 |
| Tempus Ai, Inc | $109 |
| Eisai Inc. | $81.11 |
| Karyopharm Therapeutics Inc. | $51.77 |
| Compensation for services other than consulting (speaking, faculty) | $4,625 |
|---|---|
| Consulting Fee | $2,740 |
| Food and Beverage | $1,158 |
| Travel and Lodging | $1,055 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Corcept Therapeutics Dec 23, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionADVISORY FEE | $4,625 |
| AstraZeneca Pharmaceuticals LP Jan 25, 2025 | Consulting Fee | $2,740 |
| Corcept Therapeutics Nov 5, 2025 | Travel and Lodging travel to San Francisco, CA · in-kind Company’s descriptionAIRFARE AND TRAIN | $407 |
| Intuitive Surgical, Inc. May 5, 2025 | Travel and Lodging Da Vinci Surgical System · SURGERY · travel to DALLAS, TX · in-kind | $402 |
| Corcept Therapeutics Dec 12, 2025 | Travel and Lodging travel to San Francisco, CA · in-kind Company’s descriptionLODGING | $161 |
| Corcept Therapeutics Dec 23, 2025 | Travel and Lodging travel to San Francisco, CA · in-kind Company’s descriptionTRAVEL OTHERS | $40.00 |
| Intuitive Surgical, Inc. May 5, 2025 | Travel and Lodging Da Vinci Surgical System · SURGERY · travel to DALLAS, TX · in-kind | $37.00 |
| Corcept Therapeutics Dec 23, 2025 | Travel and Lodging travel to San Francisco, CA · in-kind Company’s descriptionTRAVEL OTHERS | $8.68 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 5 companies. The companies reported $194,016 in research payments for these studies, mostly to the institutions running them.
- Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Daiichi Sankyo Inc. · Recruiting · NCT06819007 - A randomized, double-blind, phase 3 comparison of platinum-based thera
GlaxoSmithKline, LLC. - A phase ii single arm study of giredestrant in patients with grade 1 endometrial cancer
Genentech, Inc. - A phase i clinical study to evaluate the safety, tolerability, pharmac
GlaxoSmithKline, LLC. - A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Karyopharm Therapeutics Inc. - A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer KEYNOTE-B96 , ENGOT…
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.